Travere Therapeutics (NASDAQ:TVTX) Director Sells $1,352,247.50 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Roy Baynes sold 32,750 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the sale, the director directly owned 37,500 shares of the company’s stock, valued at approximately $1,548,375. This trade represents a 46.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $40.77 on Friday. The company has a market cap of $3.77 billion, a price-to-earnings ratio of -135.90 and a beta of 0.86. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $43.31. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The firm has a 50 day moving average of $29.99 and a 200-day moving average of $31.59.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s addressable U.S. patient population and underpinning multi‑year revenue upside. Filspari approval article
• Positive Sentiment: Multiple brokerages raised ratings and price targets (examples cited include Canaccord, Guggenheim, Piper Sandler and HC Wainwright), reinforcing bullish revenue and valuation revisions tied to the approval. Guggenheim note
• Neutral Sentiment: Trading and options volumes are unusually high around the approval-driven move, amplifying short‑term swings and making intraday price moves less predictive of fundamentals. Options activity report
• Neutral Sentiment: Company commentary and analyst write‑ups are clarifying label scope and launch plans but have not yet produced concrete revenue reads — useful for modeling but not definitive for near‑term earnings. Company discussion
• Negative Sentiment: Significant insider selling occurred over the last two trading days (CEO, directors, CFO, CAO and others). Most sales were via Rule 10b5‑1 plans or to cover tax withholding, but the scale of disposals can intensify near‑term downward pressure and signal profit‑taking after the approval rally. Insider trades summary
• Negative Sentiment: Some analysts caution that elevated expectations and rapid estimate revisions may limit further upside near term; the stock could consolidate or retrace as investors re‑rate forward revenue assumptions. Zacks caution

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TVTX shares. Canaccord Genuity Group lifted their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Guggenheim lifted their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. JPMorgan Chase & Co. reduced their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research report on Tuesday, April 14th. Finally, Wall Street Zen downgraded shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Travere Therapeutics by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock worth $158,059,000 after acquiring an additional 619,085 shares during the last quarter. State Street Corp boosted its holdings in Travere Therapeutics by 47.8% during the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock worth $181,752,000 after acquiring an additional 1,538,827 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Travere Therapeutics by 12.7% during the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock worth $163,469,000 after acquiring an additional 483,565 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Travere Therapeutics by 27.4% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock worth $41,203,000 after acquiring an additional 599,102 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Travere Therapeutics by 28.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock worth $85,849,000 after acquiring an additional 494,665 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.